Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans

Toxicological Sciences

Volumn 132, Issue 1, 2013, Pages 107-117

  Khetani, Salman R ^a   Kanchagar, Chitra ^b   Ukairo, Okechukwu ^b   Krzyzewski, Stacy ^b   Moore, Amanda ^b   Shi, Julianne ^b   Aoyama, Simon ^b   Aleo, Michael ^c   Will, Yvonne ^d  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b Hepregen Corporation   (United States)

^c Drug Safety Research and Development   (United States)

^d PFIZER INC   (United States)

Author keywords

Cocultures; Drug induced liver injury; Human hepatocytes; Micropatterning; Rat hepatocytes stromal cells

Indexed keywords

ACETAZOLAMIDE; ACETYLSALICYLIC ACID; ADENOSINE TRIPHOSPHATE; ALBUMIN; BENZBROMARONE; BETAHISTINE; BUSPIRONE; CAPTOPRIL; CHLORAMPHENICOL PALMITATE; CIPROFLOXACIN; CLOMIFENE CITRATE; CLOZAPINE; DEXAMETHASONE; DEXTROMETHORPHAN; DICLOFENAC; FLUOXETINE; FLURBIPROFEN; GLUTATHIONE; LIDOCAINE; MEBENDAZOLE; MEFENAMIC ACID; MICONAZOLE; PHENACETIN; PHENYLBUTAZONE; PREDNISONE; PROPRANOLOL; QUININE; TRAZODONE; UREA; WARFARIN;

ADULT; ANIMAL CELL; ARTICLE; COCULTURE; EMBRYO; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HYPOTHESIS; LIVER CELL; MALE; MICROPATTERNED COCULTURE; MOUSE; NONHUMAN; QUALITATIVE ANALYSIS; RAT; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TOXIC HEPATITIS;

ANIMALS; COCULTURE TECHNIQUES; DRUG-INDUCED LIVER INJURY; HUMANS; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; TOXICITY TESTS;

RATTUS;

EID: 84876475743     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfs326     Document Type: Article

References (30)

1. Bhatia, S. N., Balis, U. J., Yarmush, M. L., and Toner, M. (1999). Effect of cell-cell interactions in preservation of cellular phenotype: Cocultivation of hepatocytes and nonparenchymal cells. FASEB J. 13, 1883-1900.
2. Bi, Y. A., Kazolias, D., and Duignan, D. B. (2006). Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metab. Dispos. 34, 1658-1665.
3. Biagini, C. P., Boissel, E., Borde, F., Bender, V. E., Bouskila, M., Blazy, F., Nicaise, L., Mignot, A., Cassio, D., and Chevalier, S. (2006). Investigation of the hepatotoxicity profile of chemical entities using Liverbeads and WIF-B9 in vitro models. Toxicol. In Vitro 20, 1051-1059.
4. Calder, I. C., Hart, S. J., Smail, M. C., and Tange, J. D. (1981). Hepatotoxicity of phenacetin and paracetamol in the Gunn rat. Pathology 13, 757-762.
5. Chen, M., Vijay, V., Shi, Q., Liu, Z., Fang, H., and Tong, W. (2011). FDAapproved drug labeling for the study of drug-induced liver injury. Drug Discov. Today 16, 697-703.
6. Cosgrove, B. D., King, B. M., Hasan, M. A., Alexopoulos, L. G., Farazi, P. A., Hendriks, B. S., Griffith, L. G., Sorger, P. K., Tidor, B., Xu, J. J., et al. (2009). Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol. Appl. Pharmacol. 237, 317-330.
7. Dawson, S., Stahl, S., Paul, N., Barber, J., and Kenna, J. G. (2012). In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab. Dispos. 40, 130-138.
8. Grattagliano, I., Bonfrate, L., Diogo, C. V., Wang, H. H., Wang, D. Q., and Portincasa, P. (2009). Biochemical mechanisms in drug-induced liver injury: Certainties and doubts. World J. Gastroenterol. 15, 4865-4876.
9. Guillouzo, A., and Guguen-Guillouzo, C. (2008). Evolving concepts in liver tissue modeling and implications for in vitro toxicology. Expert Opin. Drug Metab. Toxicol. 4, 1279-1294.
10. Higa, F., Kitsukawa, K., Gaja, M., Tateyama, M., Shikiya, K., Shigeno, Y., Kinjo, F., and Saito, A. (1992). Cytotoxicity of mebendazole against established cell lines from the human, rat, and mouse liver. Arch. Toxicol. 66, 224-227.
11. Jurima-Romet, M., Crawford, K., and Huang, H. S. (1994). Comparative cytotoxicity of non-steroidal anti-inflammatory drugs in primary cultures of rat hepatocytes. Toxicol. In Vitro 8, 55-66.
12. Kaplowitz, N. (2005). Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 4, 489-499.
13. Khetani, S. R., and Bhatia, S. N. (2008). Microscale culture of human liver cells for drug development. Nat. Biotechnol. 26, 120-126.
14. Kovalenko, V. M., Bagnyukova, T. V., Sergienko, O. V., Bondarenko, L. B., Shayakhmetova, G. M., Matvienko, A. V., and Pogribny, I. P. (2007). Epigenetic changes in the rat livers induced by pyrazinamide treatment. Toxicol. Appl. Pharmacol. 225, 293-299.
15. Lawal, A. O., and Ellis, E. (2010). Differential sensitivity and responsiveness of three human cell lines HepG2, 1321N1 and HEK 293 to cadmium. J. Toxicol. Sci. 35, 465-478.
16. LeCluyse, E. L. (2001). Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur. J. Pharm. Sci. 13, 343-368.
17. Masubuchi, N., Makino, C., and Murayama, N. (2007). Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: Correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans. Chem. Res. Toxicol. 20, 455-464.
18. Masubuchi, Y., Konishi, M., and Horie, T. (1999). Imipramine- and mianserininduced acute cell injury in primary cultured rat hepatocytes: Implication of different cytochrome P450 enzymes. Arch. Toxicol. 73, 147-151.
19. Milosevic, N., Schawalder, H., and Maier, P. (1999). Kupffer cell-mediated differential down-regulation of cytochrome P450 metabolism in rat hepatocytes. Eur. J. Pharmacol. 368, 75-87.
20. O'Brien, P. J., Irwin, W., Diaz, D., Howard-Cofield, E., Krejsa, C. M., Slaughter, M. R., Gao, B., Kaludercic, N., Angeline, A., Bernardi, P., et al. (2006). High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol. 80, 580-604.
21. Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000). Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32, 56-67.
22. Rawlins, M. D. (2004). Cutting the cost of drug development? Nat. Rev. Drug Discov. 3, 360-364.
23. Shih, H., Pickwell, G. V., Guenette, D. K., Bilir, B., and Quattrochi, L. C. (1999). Species differences in hepatocyte induction of CYP1A1 and CYP1A2 by omeprazole. Hum. Exp. Toxicol. 18, 95-105.
24. Tolosa, L., Pinto, S., Donato, M. T., Lahoz, A., Castell, J. V., O'Connor, J. E., and Gómez-Lechón, M. J. (2012). Development of a multiparametric cellbased protocol to screen and classify the hepatotoxicity potential of drugs. Toxicol. Sci. 127, 187-198.
25. Ulrich, R. G. (2007). Idiosyncratic toxicity: A convergence of risk factors. Annu. Rev. Med. 58, 17-34.
26. Wang, W. W., Khetani, S. R., Krzyzewski, S., Duignan, D. B., and Obach, R. S. (2010). Assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites. Drug Metab. Dispos. 38, 1900-1905.
27. Watanabe, T., Sagisaka, H., Arakawa, S., Shibaya, Y., Watanabe, M., Igarashi, I., Tanaka, K., Totsuka, S., Takasaki, W., and Manabe, S. (2003). A novel model of continuous depletion of glutathione in mice treated with L-buthionine (S,R)-sulfoximine. J. Toxicol. Sci. 28, 455-469.
28. Wei, X., Loi, C. M., Jarvi, E. J., and Vestal, R. E. (1995). Relative potency of mexiletine, lidocaine, and tocainide as inhibitors of rat liver CYP1A1 activity. Drug Metab. Dispos. 23, 1335-1338.
29. Wilkening, S., Stahl, F., and Bader, A. (2003). Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. Drug Metab. Dispos. 31, 1035-1042.
30. Xu, J. J., Henstock, P. V., Dunn, M. C., Smith, A. R., Chabot, J. R., and de Graaf, D. (2008). Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci. 105, 97-105.